FDA issued a warning letter to a Chinese supplier after inspectors found alleged attempts to circumvent recently introduced GLP-1 active pharmaceutical ingredient (API) import restrictions. FDA said Harbin Jixianglong Biotech bought semaglutide from a facility not on the FDA’s “green list,” then relabeled and shipped the batches into the US. The agency highlighted gaps in batch records and documentation for repackaging and labeling, citing concerns that identifying a firm rather than the actual manufacturer could expose US consumers to substandard APIs. FDA noted that while the firm committed to prohibiting sale of externally procured products, it initially did not address concerns about batches already in the US market. The enforcement action reflects a shift toward tighter regulator oversight of high-demand GLP-1 supply chains, with compliance documentation becoming a central gate for commercial access.